TDOC vs OMCL

For growth investors, Omnicell, Inc.

(OMCL) is the stronger pick with 6. 5% revenue growth year-over-year, versus -1. 5% for Teladoc Health, Inc. (TDOC). Omnicell, Inc. (OMCL) offers the better valuation at 987. 8x trailing P/E (22. 6x forward), making it the more compelling value choice. Analysts rate Teladoc Health, Inc. (TDOC) a "Hold" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Omnicell, Inc.

(OMCL) delivered a total return of -68. 7%, compared to -95. 5% for Teladoc Health, Inc. (TDOC). Over 10 years, the gap is even starker: OMCL returned +39. 0% versus TDOC's -37. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Omnicell, Inc.

(OMCL) is the lower-risk stock at 1. 34β versus Teladoc Health, Inc. 's 1. 91β — meaning TDOC is approximately 43% more volatile than OMCL relative to the S&P 500. On balance sheet safety, Omnicell, Inc. (OMCL) carries a lower debt/equity ratio of 17% versus 75% for Teladoc Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Omnicell, Inc.

(OMCL) is pulling ahead at 6. 5% versus -1. 5% for Teladoc Health, Inc. (TDOC). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to -83. 6% for Omnicell, Inc.. Over a 3-year CAGR, TDOC leads at 1. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Omnicell, Inc.

(OMCL) is the more profitable company, earning 0. 2% net margin versus -7. 9% for Teladoc Health, Inc. — meaning it keeps 0. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OMCL leads at 0. 4% versus -10. 4% for TDOC. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for OMCL: 30.

7% to $57. 20.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Omnicell, Inc.

(OMCL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OMCL: +39. 0%, TDOC: -37. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.